Karl Tronstad: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Line 38: Line 38:
</ref> [https://insight.jci.org/articles/view/89376 (Full Text)]
</ref> [https://insight.jci.org/articles/view/89376 (Full Text)]
* 2020, Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study<ref name="Rekeland2020">{{Cite journal|last=Rekeland|first=Ingrid G.|author-link=|last2=Fosså|first2=Alexander|author-link2=|last3=Lande|first3=Asgeir|author-link3=|last4=Ktoridou-Valen|first4=Irini|author-link4=|last5=Sørland|first5=Kari|author-link5=|last6=Holsen|first6=Mari|author-link6=|last7=Tronstad|first7=Karl J.|author-link7=Karl Tronstad|last8=Risa|first8=Kristin|author-link8=|last9=Alme|first9=Kine|author-link9=|date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Frontiers in Medicine|language=English|volume=7|issue=162|pages=|doi=10.3389/fmed.2020.00162|issn=2296-858X|pmc=|pmid=|access-date=|quote=|via=|last10=Viken|first10=Marte K.|author-link10=|last11=Lie|first11=Benedicte K.|author-link11=|last12=Dahl|first12=Olav|author-link12=|last13=Mella|first13=Olav|author-link13=Olav Mella|first14=Øystein|last14=Fluge|author-link14=Øystein Fluge}}</ref> - [https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full? (Full text)]
* 2020, Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study<ref name="Rekeland2020">{{Cite journal|last=Rekeland|first=Ingrid G.|author-link=|last2=Fosså|first2=Alexander|author-link2=|last3=Lande|first3=Asgeir|author-link3=|last4=Ktoridou-Valen|first4=Irini|author-link4=|last5=Sørland|first5=Kari|author-link5=|last6=Holsen|first6=Mari|author-link6=|last7=Tronstad|first7=Karl J.|author-link7=Karl Tronstad|last8=Risa|first8=Kristin|author-link8=|last9=Alme|first9=Kine|author-link9=|date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Frontiers in Medicine|language=English|volume=7|issue=162|pages=|doi=10.3389/fmed.2020.00162|issn=2296-858X|pmc=|pmid=|access-date=|quote=|via=|last10=Viken|first10=Marte K.|author-link10=|last11=Lie|first11=Benedicte K.|author-link11=|last12=Dahl|first12=Olav|author-link12=|last13=Mella|first13=Olav|author-link13=Olav Mella|first14=Øystein|last14=Fluge|author-link14=Øystein Fluge}}</ref> - [https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full? (Full text)]
* 2021, A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome<ref>{{Cite journal|last=Hoel|first=Fredrik|last2=Hoel|first2=August|last3=Pettersen|first3=Ina K.N.|last4=Rekeland|first4=Ingrid G.|last5=Risa|first5=Kristin|last6=Alme|first6=Kine|last7=Sørland|first7=Kari|last8=Fosså|first8=Alexander|last9=Lien|first9=Katarina|date=2021-08-23|title=A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome|url=https://insight.jci.org/articles/view/149217|journal=JCI Insight|language=en|volume=6|issue=16|pages=e149217|doi=10.1172/jci.insight.149217|issn=2379-3708}}</ref> - [https://insight.jci.org/articles/view/149217 (Full text)]
* 2021, A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome<ref>{{Cite journal|last=Hoel|first=Fredrik|last2=Hoel|first2=August|last3=Pettersen|first3=Ina K.N.|last4=Rekeland|first4=Ingrid G.|last5=Risa|first5=Kristin|last6=Alme|first6=Kine|last7=Sørland|first7=Kari|last8=Fosså|first8=Alexander|last9=Tronstad|first9=Karl J.|date=2021-08-23|title=A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome|url=https://insight.jci.org/articles/view/149217|journal=JCI Insight|language=en|volume=6|issue=16|pages=e149217|doi=10.1172/jci.insight.149217|issn=2379-3708|pmc=|pmid=|quote=|author-link=|author-link2=|access-date=|author-link3=|author-link4=|author-link5=|author-link6=|via=}}</ref> - [https://insight.jci.org/articles/view/149217 (Full text)]


= Talks and interviews =
= Talks and interviews =

Revision as of 11:01, August 27, 2021

Karl Tronstad.png

Karl Johan Tronstad, PhD, is a professor in the Department of Biomedicine, University of Bergen, Bergen, Norway, where he heads the Tronstad Lab which studies cell metabolism and mitochondrial involvement in cancer and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). In 2017, his research group received a grant of 9.5 million for the development of new ME/CFS treatment methods and biomarkers. Dr. Tronstad collaborates with Professor Olav Mella and Øystein Fluge at the Department of Oncology and Medical Physics at Haukeland University Hospital on ME/CFS research.[1]

Notable studies[edit | edit source]

  • 2016, Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome[2] (Full Text)
  • 2020, Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study[3] - (Full text)
  • 2021, A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome[4] - (Full text)

Talks and interviews[edit | edit source]

  • 2019, Speaker at the 14th Invest in ME International ME Conference; Speech title: Metabolic profiling and associations to clinical data in ME - (Video)

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. "Finding the cause of Chronic Fatigue Syndrome/ME". University of Bergen. Retrieved March 7, 2021.
  2. Fluge, Øystein; Mella, Olav; Bruland, Ove; Risa, Kristin; Dyrstad, Sissel E.; Alme, Kine; Rekeland, Ingrid G.; Sapkota, Dipak; Røsland, Gro V.; Fosså, Alexander; Ktoridou-Valen, Irini; Lunde, Sigrid; Sørland, Kari; Lien, Katarina; Herder, Ingrid; Thürmer, Hanne; Gotaas, Merete E.; Baranowska, Katarzyna A.; Bohnen, Louis M.L.J.; Schäfer, Christoph; McCann, Adrian; Sommerfelt, Kristian; Helgeland, Lars; Ueland, Per M.; Dahl, Olav; Tronstad, Karl J. (2016), "Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome", JCI Insight, 1 (21), doi:10.1172/jci.insight.89376
  3. Rekeland, Ingrid G.; Fosså, Alexander; Lande, Asgeir; Ktoridou-Valen, Irini; Sørland, Kari; Holsen, Mari; Tronstad, Karl J.; Risa, Kristin; Alme, Kine; Viken, Marte K.; Lie, Benedicte K.; Dahl, Olav; Mella, Olav; Fluge, Øystein (2020). "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study". Frontiers in Medicine. 7 (162). doi:10.3389/fmed.2020.00162. ISSN 2296-858X.
  4. Hoel, Fredrik; Hoel, August; Pettersen, Ina K.N.; Rekeland, Ingrid G.; Risa, Kristin; Alme, Kine; Sørland, Kari; Fosså, Alexander; Tronstad, Karl J. (August 23, 2021). "A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome". JCI Insight. 6 (16): e149217. doi:10.1172/jci.insight.149217. ISSN 2379-3708.